哪里想瘦打哪里！FDA批准Kythera针头药物上市在即

你才双下巴，你全家都双下巴！只不过小姑娘自是人皆有之。如果说赘肉是每一个渴望占有极致身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴可谓是这些人的生死仇敌了。每一分钟，世界各地都有人为自己的一张大饼脸而感到烦恼，虽然占有一个肉感十足的双下巴指头上去是挺有肉感的，但是还是有很多人的判断力使其无法负荷一个双下巴之重。您可千万别痴，这甚至已经催生成一个庞大的市场需求。根据美国面部牙科总可能会的报告研究显示，68%的白人对自己的双下巴声称了“不感兴趣”之情。而有鉴于，近期Kythera日本公司向FDA提请了其专为歼灭双下巴的瘦身服用式本品ATX-101。这种本品完成了许多“胖纸”梦寐以求的机制，哪里想瘦打哪里，可谓是定点失眠。不要以为这种近乎任性的本品只是一个痴话，在FDA的下属的面部和诊疗本品专员可能会的无记名投票选举中都，研究者可是以17：0的超高支持票一致赞成其上市。也许是因为这些研究者中都也有很多招致双下巴之苦吧。FDA也将计划于来年的5月13日之前对其作成最后决定。如果一切顺利的话，Kythera日本公司计划于来年下半年将该产品上市，统计分析香港市民原订这一本品的交易额将超过3亿美元之多。随着瘦身本品市场需求的大为增大，Kythera日本公司可谓是下了一步好棋。日本公司于去年以8400万美元的定价从其前合作标下手上转让了这种本品的全部公民权。而Kythera日本公司也渴望以此为契机在瘦身本品市场需求中都固守拔寨。就在上个月，Kythera日本公司和Actelion日本公司和解价值2700万美元的合作协议，所设计一种失败过的抗炎症本品，而这种本品被认为无论如何开发新成一种治疗皮肤炎的本品。详细全名报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.